Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 4/20 | 0.66 |
| ▸ | PRKCA | P17252 | 4/20 | 0.57 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.57 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.57 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
| ▸ | DGKA | P23743 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL571263 | 0.98 | MAPT (0.70) | MAPTMAPK1LMNAPRKCAPRKCE | |
| SCHEMBL26973 | 0.98 | MAPT (0.70) | MAPTMAPK1LMNAPRKCAPRKCE | |
| SCHEMBL16701295 | 0.98 | MAPT (0.70) | MAPTMAPK1LMNAPRKCAPRKCE | |
| SCHEMBL4797376 | 0.98 | MAPT (0.70) | MAPTMAPK1LMNAPRKCAPRKCE | |
| SCHEMBL20263545 | 0.98 | MAPT (0.70) | MAPTMAPK1LMNAPRKCAPRKCE | |
| SCHEMBL343318 | 0.98 | MAPT (0.70) | MAPTMAPK1LMNAPRKCAPRKCE | |
| SCHEMBL1695881 | 0.98 | MAPT (0.70) | MAPTMAPK1LMNAPRKCAPRKCE | |
| SCHEMBL9011176 | 0.94 | MAPT (0.58) | MAPTMAPK1LMNAPRKCAPRKCE | |
| Propene SCHEMBL20819808 | 0.90 | MAPT (0.60) | MAPTMAPK1LMNAPRKCAPRKCE | |
| SCHEMBL144890 | 0.88 | PRKCA (0.66) | MAPTMAPK1LMNAPRKCAPRKCE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8592621-B2 | Precursor compounds of sweet taste receptor antagonists for the prevention or treatment of disease | SYMRISE AG (DE) | 2013-11-26 | — | — | US | claimed |
| US-20110045069-A1 | PRECURSOR COMPOUNDS OF SWEET TASTE RECEPTOR ANTAGONISTS FOR THE PREVENTION OR TREATMENT OF DISEASE | SYMRISE GMBH CO. KG (DE) | 2011-02-24 | — | — | US | claimed |
| JP-9316007-A | — | — | None | — | — | JP | disclosed |
| US-20240410055-A1 | METHOD AND FORMULATION FOR PREPARING OPTICAL METAL OXIDE LAYERS | MERCK PATENT GMBH (DE) | 2024-12-12 | — | — | US | disclosed |
| WO-2023057401-A1 | METHOD AND FORMULATION FOR PREPARING OPTICAL METAL OXIDE LAYERS | MERCK PATENT GMBH (DE) | 2023-04-13 | — | — | WO | disclosed |
| CN-115551470-A | Synergistic preservative/personal care compositions containing alkylene glycol esters | 奥麒英国生物灭杀剂有限公司 | 2022-12-30 | — | — | CN | disclosed |
| CN-108473484-B | Compounds useful as TRPM8 modulators | 弗门尼舍公司 | 2021-06-29 | — | — | CN | disclosed |
| CN-111565721-A | Composition comprising ibrutinib and an alkaloid with enhanced bioavailability | 西普拉有限公司 | 2020-08-21 | — | — | CN | disclosed |
| US-8592621-B2 | Precursor compounds of sweet taste receptor antagonists for the prevention or treatment of disease | SYMRISE AG (DE) | 2013-11-26 | — | — | US | disclosed |
| US-20110045069-A1 | PRECURSOR COMPOUNDS OF SWEET TASTE RECEPTOR ANTAGONISTS FOR THE PREVENTION OR TREATMENT OF DISEASE | SYMRISE GMBH CO. KG (DE) | 2011-02-24 | — | — | US | disclosed |
| JP-H09316007-A | LOCALLY APPLICABLE COMPOSITION | ADVANCED SUKIN RES KENKYUSHO:KK | 1997-12-09 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110045069-A1 | PRECURSOR COMPOUNDS OF SWEET TASTE RECEPTOR ANTAGONISTS FOR THE PREVENTION OR TREATMENT OF DISEASE | TAS1R2, TAS2R5, TAS2R1 | MAPT 3623/4885MAPK1 2309/4885LMNA 3996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.